19 October 2018 - The High Court has dismissed the ACCC’s application to appeal a decision on whether Pfizer’s local unit used its market power to limit competition for a cholesterol lowering drug.

The Australian Competition and Consumer Commission sought leave to appeal against a judgment by a Federal Court in May, when Pfizer was alleged to have abused its market power by offering big discounts and rebates on Lipitor to pharmacies.

The drug stores were said to have bought large quantities and agreed to limit re-supply of competing generic atorvastatin products.

Read The Australian article